Fred Aslan is the founder of Artiva Biotherapeutics. Artiva Biotherapeutics has raised $167M in total funding. Latest round: IPO.
Fred Aslan, M.D., became CEO of Artiva Biotherapeutics in January 2021. He guided the company through its transition from preclinical to clinical-stage, which included securing Series B financing and an IPO. He focuses on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers, and also serves as President.
Full founder directory · Investor directory · Company funding database · Fundraising library